Guo Qian, Lv Shuang, Wang Bingping, Li Yinbing, Cha Nier, Zhao Ruigang, Bao Wenhua, Jia Baoqing
Breast Neoplasms Surgical Department, Inner Mongolia People's Hospital, Huhehot, Inner Mongolia 010010, P.R. China.
Department of Oncology, Inner Mongolia People's Hospital, Huhehot, Inner Mongolia 010010, P.R. China.
Exp Ther Med. 2019 Dec;18(6):4547-4554. doi: 10.3892/etm.2019.8152. Epub 2019 Oct 31.
Long non-coding RNAs (lncRNAs) have important roles in the development and progression of various types of human cancer. However, the expression and function of the lncRNA prostate cancer-associated non-coding RNA 1 (PRNCR1) in breast cancer remains unclear. Reverse transcription-quantitative PCR was performed to measure the levels of mRNA expression. Cell counting kit-8, flow cytometry, wound healing and Transwell assays were also performed to study cell proliferation, cell cycle, migration and invasion, respectively. The results of the present study revealed that PRNCR1 expression levels were higher in breast cancer tissues compared with adjacent normal tissues in a patient study. It was also determined that high expression of PRNCR1 was significantly associated with advanced clinical stage, positive metastasis and poor prognosis for patients with breast cancer. experiments determined that PRNCR1 was significantly upregulated in the breast cancer cell lines BT-549, MCF-7, SK-BR-3 and MDA-MB-231 compared with the normal human breast cell line, MCF-10A. Silencing of PRNCR1 significantly inhibited the proliferation, colony formation, cell cycle progression, migration and invasion of SK-BR-3 and BT-549 cells, while cell apoptosis was induced. In addition, knockdown of PRNCR1 suppressed epithelial-mesenchymal transition in SK-BR-3 and BT-549 cells. In summary, the present results demonstrated that lncRNA PRNCR1 was significantly upregulated in breast cancer and was associated with cancer progression and poor patient prognosis. experiments determined that knockdown of PRNCR1 inhibited the malignant phenotypes of breast cancer cells. Taken together, the results indicated that PRNCR1 may be used as a potential therapeutic target for patients with breast cancer.
长链非编码RNA（lncRNAs）在各类人类癌症的发生和发展过程中发挥着重要作用。然而，lncRNA前列腺癌相关非编码RNA1（PRNCR1）在乳腺癌中的表达及功能仍不清楚。采用逆转录定量PCR检测mRNA表达水平。同时进行细胞计数试剂盒-8、流式细胞术、伤口愈合和Transwell实验，分别研究细胞增殖、细胞周期、迁移和侵袭情况。本研究结果显示，在一项患者研究中，与相邻正常组织相比，乳腺癌组织中PRNCR1表达水平更高。还确定PRNCR1的高表达与乳腺癌患者的晚期临床分期、阳性转移及不良预后显著相关。实验确定，与正常人乳腺细胞系MCF-10A相比，PRNCR1在乳腺癌细胞系BT-549、MCF-7、SK-BR-3和MDA-MB-231中显著上调。沉默PRNCR1可显著抑制SK-BR-3和BT-549细胞的增殖、集落形成、细胞周期进程、迁移和侵袭，同时诱导细胞凋亡。此外，敲低PRNCR1可抑制SK-BR-3和BT-549细胞中的上皮-间质转化。总之，本研究结果表明lncRNA PRNCR1在乳腺癌中显著上调，并与癌症进展及患者不良预后相关。实验确定敲低PRNCR1可抑制乳腺癌细胞的恶性表型。综上所述，结果表明PRNCR1可能作为乳腺癌患者的潜在治疗靶点。
